Allows Medicare to negotiate the price of certain prescription drugs to bring down the price beneficiaries will pay for their medications and limits the price growth of certain drugs due to inflation by having a $2,000 cap on the annual out-of-pocket prescription drug costs for Medicare recipients starting in 2025. It also repeals the implementation of the “rebate rule,” which is scheduled to increase drug-related Medicare costs beginning in 2027, and redesigns the Medicare Part D benefit formula. This can impact the bottom line and cash flow projections of various healthcare, pharmaceutical, and other life sciences and drug related companies. This can also affect pricing schemes and inventory valuation to Net Realizable Values.